Back to Search Start Over

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

Authors :
De Leeuw, Elisabeth
Van Damme, Karel F. A.
Declercq, Jozefien
Bosteels, Cedric
Maes, Bastiaan
Tavernier, Simon J.
Detalle, Laurent
Smart, Trevor
Glatt, Sophie
Debeuf, Nincy
Deckers, Julie
Lameire, Sahine
Vandecasteele, Stefaan J.
De Neve, Nikolaas
Demedts, Ingel K.
Govaerts, Elke
Knoop, Christiane
Vanhove, Karolien
Moutschen, Michel
Terryn, Wim
Depuydt, Pieter
Van Braeckel, Eva
Haerynck, Filomeen
Hendrickx, Tine C. J.
Parrein, Vanessa
Lalla, Marianna
Brittain, Claire
Lambrecht, Bart N.
Publication Year :
2022
Publisher :
figshare, 2022.

Abstract

Additional file 7: Table S1. Primary and supportive endpoints in the full analysis data set. LSMean, least square mean; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; CI, confidence interval; SD, standard deviation. *Based on the highest temperature in 24 h. Table S2. Follow-up endpoints. SD, standard deviation; DLCO, diffusing capacity of lung for carbon monoxide; HRCT, high-resolution computed tomography; WHO, world health organisation. 6-point ordinal scale: 2 on invasive mechanical ventilation; 3 on non-invasive ventilation or high flow oxygen devices; 4 hospitalized, requiring supplemental oxygen; 5 hospitalized, not requiring supplemental oxygen, 6 not hospitalized.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....8842fb2c25aa31faf98478fede16e49a
Full Text :
https://doi.org/10.6084/m9.figshare.20462401